The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Dividend puts strain on Pfizer

It's not a new question, but it's one whose urgency is growing: How long can Pfizer pay its big dividend? It's the largest in the industry, at 6.67 percent compared with 3.37 percent pharma-wide.

Avant shares soar on positive cancer vaccine data

On the same day that Ted Kennedy was undergoing brain surgery to remove a tumor,

ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...

> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent.

New Chantix scrips drop by almost half

Talk about an image being worth a thousand words. A Wall Street Journal chart tracking new Chantix prescriptions since January shows the kind of downward slope you only want to see on a double black

Pfizer strikes back with Chantix ads

Hit by new concerns about the safety of its stop-smoking drug Chantix, Pfizer is hitting back with an advertising and PR campaign. And no wonder: The drugmaker has been counting on that drug, with

Facebook, Twitter, etc., new marketing tools

It's a brave new pharma-marketing world out there, with more and more hospitals and docs barring drug reps and companies turning to electronic detailing to get their messages across. But the online

Pfizer taps litigator as new GC

Say hello to Pfizer's new general counsel, Amy Schulman (photo), a top litigator who's served as lead attorney on

GSK offers pilots a Chantix alternative

Exploiting a competitor's weakness is a time-honored tradition in business. So it's probably no surprise that GlaxoSmithKline is injecting itself into the

Truckers on Chantix can't be licensed

Trucking regulators have joined the FAA in banning Pfizer's stop-smoking drug among its drivers. The Federal Motor Carrier Safety Administration yesterday said Chantix patients shouldn't be

Chantix side-effects news prompts FAA ban

Chantix suffered a one-two punch yesterday, as a watchdog group's report linked the stop-smoking med to a wide variety of health and safety problems, and the Federal Aviation Administration told